Source comparison
TB-500 Wound Healing Protocols: Research Model Comparison
Acute Soft Tissue Injury Twice weekly 2.5mg 4 weeks Actin upregulation, early-phase angiogenesis Effective for muscle strains and ligament tears with minimal inflammation. Cease dosing once acute phase resolves. Prolonged use doesn't improve outcomes. Chronic
This comparison does not assign a generated winner or score.
- Acute Soft Tissue Injury
- Twice weekly
- 2.5mg
- 4 weeks
- Actin upregulation, early-phase angiogenesis
- Effective for muscle strains and ligament tears with minimal inflammation. Cease dosing once acute phase resolves. Prolonged use doesn't improve outcomes.
- Chronic Non-Healing Wound
- 5mg
- 6–8 weeks
- VEGF expression, fibroblast migration into hypoxic zones
- Higher dose compensates for baseline inflammatory cytokine burden in diabetic or ischemic models. Monitor for infection. TB-500 doesn't address microbial colonisation.
- Post-Surgical Incision Healing
- Once weekly
- 2mg
- 3 weeks
- Keratinocyte migration, reduced scar formation
- Lower frequency matches surgical wound closure timelines. Start 48 hours post-op once haemostasis is established. Earlier dosing interferes with clot formation.
- Tendon/Ligament Repair
- 8–12 weeks
- Collagen Type I deposition, tenoblast proliferation
- Longest protocol duration due to slow collagen remodelling phase. Combine with mechanical loading protocols for maximal tensile strength recovery.